ProCE Banner Activity

Optimizing Outcomes in Gynecological Cancer: Patient Survey Results

Clinical Thought
Shannon N. Westin, MD, MPH, shares her takeaways from a patient preference survey administered to patients with gynecologic cancers covering topics such as cancer biomarkers guiding therapy and adverse events considerations.

Released: September 23, 2021

Expiration: September 22, 2022

Share

Faculty

Shannon N. Westin

Shannon N. Westin, MD, MPH

Associate Professor
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

GlaxoSmithKline

Merck Sharp & Dohme Corp.

Partners

Smart Patients

ProCE Banner

Faculty Disclosure

Primary Author

Shannon N. Westin, MD, MPH

Associate Professor
Division of Surgery
Department of Gynecologic Oncology and Reproductive Medicine
University of Texas MD Anderson Cancer Center
Houston, Texas

Shannon N. Westin, MD, MPH, has disclosed that she has received consulting fees from Agenus, AstraZeneca, Clovis Oncology, Eisai, EQRx, GlaxoSmithKline, Lilly, Merck, Mereo, Novartis, Pfizer, Roche/Genentech, and Zentalis and funds for research support from AstraZeneca, Bayer, Bio-Path, Clovis Oncology, Cotinga, GlaxoSmithKline, Mereo, Novartis, and Roche/Genentech.